Zenas BioPharma (ZBIO) Non-Current Debt (2025 - 2026)

Zenas BioPharma (ZBIO) posted quarterly Non-Current Debt of $72.1 million for Q1 2026, down 8.33% quarter-over-quarter from $78.6 million in Q4 2025.

Zenas BioPharma (ZBIO) Non-Current Debt (2025 - 2026) Analysis & Trends

Zenas BioPharma's Non-Current Debt history runs 2 years deep, the most recent figure standing at $72.1 million for Q1 2026.

In Q1 2026, Non-Current Debt changed N/A year-over-year to $72.1 million; the TTM figure through Mar 2026 stood at $72.1 million (changed N/A YoY), while the FY2025 annual figure was $78.6 million, changed N/A from the prior year.
Non-Current Debt for Q1 2026 stood at $72.1 million, down from $78.6 million in the prior quarter.
The five-year high for Non-Current Debt was $78.6 million in Q4 2025, with the low at $72.1 million in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	222.96 Mn

Download Data